DOCSLIB.ORG

FORMULATION and EVALUATION of a MEDICATED NAIL LACQUER for the TREATMENT of ONYCHOMYCOSIS ASWANI V M Under the Guidance of DEPAR

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FORMULATION and EVALUATION of a MEDICATED NAIL LACQUER for the TREATMENT of ONYCHOMYCOSIS ASWANI V M Under the Guidance of DEPAR FORMULATION AND EVALUATION OF A MEDICATED NAIL LACQUER FOR THE TREATMENT OF ONYCHOMYCOSIS Dissertation work submitted to The Tamilnadu Dr.M.G.R. Medical University ,Chennai In partial Fulfillment for the award of degree of MASTER OF PHARMACY IN PHARMACEUTICS Submitted by ASWANI V M Reg NO.261310753 Under the guidance of Dr. R.MANAVALAN, M.pharm, PhD Professor & Head Department of Pharmaceutics R.V.S College of pharmaceutical Sciences Sulur,Coimbatore (October 2015) DEPARTMENT OF PHARMACEUTICS R.V.S COLLEGE OF PHARMACEUTICAL SCIENCES SULUR, COIMBATORE-641 402, TAMIL NADU. Certificates Evaluation Certificate Dissertation title : FORMULATION AND EVALUATION OF A MEDICATED NAIL LACQUER FOR THE TREATMENT OF ONYCHOMYCOSIS Name of the Candidate : ASWANI V M Course of study : Master of Pharmacy in Pharmaceutics, Institution Name : R V S College of Pharmaceutical Sciences, Sulur, Coimbatore- 641 402 INTERNAL EXAMINER EXTERNAL EXAMINER PLACE: Coimbatoore DATE: Certificate This is to certify that the dissertation work entitled “FORMULATION AND EVALUATION OF A MEDICATED NAIL LACQUER FOR THE TREATMENT OF ONYCHOMYCOSIS “ is a bonafide work done by Aswani V M, RVS college of Pharmaceutical Sciences, Sulur, Coimbatore, for the partial fulfillment of the University rules and regulations for the award of Master of Pharmacy in Pharmaceutics under my guidance and supervision during the academic year 2015-16. Dr.R. MANAVALAN, M.pharm, PhD Professor and Head Department of Pharmaceutics R.V.S College of pharmaceutical Sciences Sulur, Coimbatore-641 402 Dr.R.VENKATANARAYANAN,M.Pharm,PhD Principal R.V.S College of Pharmaceutical Sciences Sulur, Coimbatore-641 402 Certificate This is to certify that the dissertation work entitled “FORMULATION AND EVALUATION OF A MEDICATED NAIL LACQUER FOR THE TREATMENT OF ONYCHOMYCOSIS“ is a bonafide work done by Aswani V M under my direct guidance for the partial fulfillment of the award of degree of Master of Pharmacy in Pharmaceutics, RVS college of Pharmaceutical Sciences, Sulur, Coimbatore, affiliated to The Tamil nadu Dr.M.G.R Medical University ,Chennai. Dr. R. MANAVALAN, M.pharm, PhD Professor and Head Department of Pharmaceutics R.V.S College of Pharmaceutical Sciences Sulur, Coimbatore-641 402 Place: Coimbatoore Date: Certificate This is to certify that the dissertation work entitled “FORMULATION AND EVALUATION OF A MEDICATED NAIL LACQUER FOR THE TREATMENT OF ONYCHOMYCOSIS“ is a bonafide work done by Aswani V M under the guidance of under the guidance of Dr. R. MANAVALAN, M -Pharm,Ph.D in the department of pharmaceutics,in the partial fulfillment of the awsard of degree of Master of Pharmacy in Pharmaceutics,R V S College of Pharmaceutical Sciences,Sulur,Coimbatoore,affiliated to the Tamilnadu Dr.M.G.R Medical University,chennai. Dr.R.VENKATANARAYANAN,M.Pharm,PhD Principal R.V.S College of Pharmaceutical Sciences Sulur,Coimbatore. ACKNOWLEDGEMENT In the name of God, The Most Gracious ,The Most Merciful… At the very outset,I thank my Lord for His Blessing and support in completing this project work. In the first place, I would like to record my sincere and heartfelt gratitude to my Institution Guide Dr.R.Manavalan, M-Pharm, Ph.D ,Professor and head,RVS college of Pharmaceutical Sciences,Sulur,Coimbatore for her supervision,advice and inspiring guidance throughout my dissertation work. Above all, she provided me unflinching encouragement and support. Let me sincerely thank Dr. R. Venkatanarayanan , Professor and Principal, RVS college of Pharmaceutical Sciences, Sulur, Coimbatore for his inspirations and being a great facilitator. Let me express my sincere gratitude to Mr. Barish for his meticulous guidance and encouragement provided to me for the completion of my dissertation work. Let me express my sincere thanks to all the staffs in Hikma herbs Pvt.Ltd. and special thanks to my industrial guide Mr. Vipin K V. Let me express my sincere thanks to my classmates and to all my well-wishers without whose inspiration and suggestions, my work would have been incomplete. Above all,I dedicate myself for the constant love and encouragement given to me by my beloved parents who deserve the credit of success in whatever work I did. ASWANI V M Abstract ABSTRACT Onychomycosis (also known as dermatophytic onychomycosis or Tinea unguium is a fungal infection of the nail. The causative pathogens of onychomycosis include dermatophytes, Candida, and nondermatophytic molds. In the present work, a medicated antifungal nail lacquer of Miconazole nitrate has been developed. The objective of the study was to deliver a sustained release of Miconazole nitrate over extended period of time up to 48 hours, and hence reduce the frequency of administration. This was expected to improve clinical efficacy and also improve the patient compliance. The nail lacquer formulation were prepared by simple mixing and analyzed for non -volatile content, gloss, smoothness to flow, drug diffusion studies, drug content estimation, anti -microbial studies. Among all formulation, nail lacquer prepared with 2% Miconazole nitrate, 6% nitrocellulose, 1% ethyl cellulose, 15 % salicylic acid, 10% propylene glycol and 10% 2-H- β-CD exhibited good non- volatile content, drug release, drug content estimation and zone of inhibition. The drug release could be extended up to 48 hour and a complete release of 98.12% was observed. FTIR studies reveled that drug and excipients are compatible. Accelerated stability study of selected optimized formulation, F11 was done as per ICH guidelines for 1 month at 40±20C, which revealed that no significant change with respect to the initial characteristics was observed. Formulation and usage of these systems are considered to be safe, without any complication. So we can conclude that the antifungal nail lacquer may be one of the novel dosage forms that can revolutionize the pharmaceutical and health care sector. LIST OF ABBREVIATIONS mm Millimeter µ Micron % Percentage e.g. Example OM Onychomycosis PAS Periodic acid Schiff MIC Minimal inhibitory concentration FDA Food and drug administration h or hr. Hour pH Hydrogen ion concentration Da Dalton SH Sulfhydryl group SC Subcutaneous V/cm Volt per centimeter HP- β- CD Hydroxyl propyl- β-cyclodextrin λmax Wave length of maximum absorption FTIR Fourier Transform Infrared CAS No Chemical abstracts service ⁰C Degree centigrade g/mol Gram per mol ICH International Conference on Harmonisation mg Milligram mPa S Millipascal second PO Per os (by mouth) ml Milliliter CP Centipoise USP United states pharmacopoeia ⁰F Degree farenheat mmHg Millimeters of mercury PG Propylene glycol AR grade Analytical reagent grade BP British Pharmacopoeia JP Journal of Perinatology USPNF United states pharmacopoeia and National Formulary OTC Over the Counter uv Ultraviolet M Molar concentration PBS Phosphate buffer solution RH Relative humidity MALDI- Matrix-assisted laser desorption/ionization time-of- TOFMS flight mass spectrometry IP Indian Pharmacopoeia IR Infrared Sec Seconds TABLE OF CONTENTS S.NO. CONTENTS PAGE NO. 1 Introduction 1 2 Aim and Objectives of 25 study 3 Review of Literature 27 4 Drug and Polymer 33 Profile 5 Materials And Methods 42 6 Results And 54 Discussion 7 Summary 79 8 Conclusion 80 9 Bibliography 82 LIST OF TABLES TABLE TITLE PAGE NO. NO. 1 Treatment and mycological 12 cure rates 2 Properties of miconazole 33 nitrate 3 Properties of Nitrocellulose 35 4 Properties of Ethylcellulose 37 5 Properties of 2- 39 Hydroxypropyl -β- Cyclodextrin 6 Properties of Salicylic Acid 40 7 Properties of Propylene Glycol 41 8 List of materials used 42 9 List of equipments used 43 10 Drug- polymer compatibility 46 study 11 Optimization of nitrocellulose 47 film former 12 Formulation of Nail Lacquer 50 13 Standard curve data for 55 Miconazole nitrate in phosphate buffer of pH 7.4 14 Solubility studies of 56 miconazole nitrate 15 FTIR Compatibility study 61 interpretation 16 Optimization of nitrocellulose 64 film former 17 Water (W) resistance of nail 64 lacquers 18 Nonvolatile content of nail 65 lacquers. 19 Drying time of nail lacquers 66 20 Viscosity of nail lacquers 67 21 Adhesive strength of nail 67 lacquers 22 Percentage drug content 68 23 Comparative study and 70 optimization of salicylic acid concentration 24 Comparative study and 71 optimization of 2-HP- β-CD concentration 25 Comparative study and 72 optimization of Ethyl cellulose concentration 26 Comparison of drug diffusion 74 across artificial membrane and hoof’s membrane 27 Zone of inhibition of miconazole 76 nitrate Nail lacquers 28 Stability studies data of F11 76 29 Invitro Diffusion profile of F11 77 upon stability studies LIST OF FIGURES FIGURE TITLE PAGE NO. NO. 1 Structure of human nail 2 2 Nail anatomy 5 3 Classification of 9 onychomycosis 4 Structure of miconazole 33 nitrate 5 Structure of Nitrocellulose 35 6 Structure of Ethyl cellulose 38 7 Structure of β-cyclodextrin (7 38 glucose units) 8 Structure of salicylic acid 40 9 Structure of propylene glycol 41 10 Tensile strength apparatus 49 11 Schematic representation of 50 preparation of nail lacquer 12 UV spectrum of Miconazole 54 nitrate in phosphate buffer solution of pH 7.4 13 Calibration curve of 55 Miconazole nitrate in phosphate buffer solution pH 7.4 14 IR spectra of Miconazole 57 nitrate 15 IR spectra of Nitrocellulose 57 16 IR spectra of Ethyl cellulose 58 17 IR spectra of beta hydroxyl 58 propyl cellulose 18 IR spectra of Miconazole 59 nitrate and Nitrocellulose 19 IR spectra of Miconazole 59 nitrate and beta hydroxyl propyl cellulose 20 IR spectra of Miconazole 60
Load more

Recommended publications
  • (10) Patent No.: US 9517190 B2
    USO09517190B2 (12) United States Patent (10) Patent No.: US 9,517,190 B2 Johncock et al. (45) Date of Patent: Dec. 13, 2016 (54) COATED TITANIUM DIOXIDE TO REDUCE (2013.01); A61K 9/5021 (2013.01); A61 K THE WHITENING EFFECT ON SKN 9/5089 (2013.01); A61O 1704 (2013.01); C09C I/3661 (2013.01); C09C I/3669 (71) Applicant: Symrise AG, Holzminden (DE) (2013.01); C09C I/3692 (2013.01); A61 K 2800/413 (2013.01); A6 IK 2800/622 (72) Inventors: William Johncock, Reinbek (DE); (2013.01); A61 K 2800/63 (2013.01) Simone Peters, Buchholz (DE): (58) Field of Classification Search Martina Issleib, Hoisdorf (DE); CPC ............................ A61K 9/5021: A61K 9/5089 Jirgen Claus, Bevern (DE) See application file for complete search history. (73) Assignee: Symrise AG, Holzminden (DE) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S. PATENT DOCUMENTS U.S.C. 154(b) by 0 days. 3,649,321 A 3, 1972 Durrant et al. (21) Appl. No.: 14/661,4879 8,545,891 B1 10/2013 Halpern et al. (22) Filed: Mar 18, 2015 FOREIGN PATENT DOCUMENTS e JLV9 O O WO 2009/126859 A2 10/2009 (65) Prior Publication Data WO 2012, 110302 A2 8, 2012 US 2015/026551 O A1 Sep. 24, 2015 WO 2012110302 A2 * 8, 2012 ....... A61K 2800,622 * cited by examiner (30) Foreign Application Priority Data Mar. 18, 2014 (EP) ..................................... 14160519 Primary Examiner — Carlos Azpuru (74) Attorney, Agent, or Firm — Dilworth & Barrese, (51) Int. Cl. LLP A6LX 9/50 (2006.01) A6 IK 8/29 (2006.01) A6 IK 8/26 (2006.01) (57) ABSTRACT set, 3,4.
    [Show full text]
  • Transdermal and Transbuccal Drug Delivery
    TRANSDERMAL AND TRANSBUCCAL DRUG DELIVERY: ENHANCMENT USING IONTOPHORESIS AND CHEMICAL ENHANCERS by LONSHENG HU A Dissertation submitted to the Graduate School-New Brunswick Rutgers, The State University of New Jersey in partial fulfillment of the requirements for the degree of Doctor of Philosophy Graduate Program in Pharmaceutical Science written under the direction of Bozena Michniak-Kohn and approved by ________________________ ________________________ ________________________ ________________________ New Brunswick, New Jersey October, 2010 ABSTRACT OF THE DISSERTATION TRANSDERMAL AND TRANSBUCCAL DRUG DELIVERY: ENHANCMENT USING IONTOPHORESIS AND CHEMICAL ENHANCERS By LONSHENG HU Dissertation Director: Professor Bozena Michniak-Kohn Transdermal and transbuccal routes offer attractive alternatives for systemic delivery of drugs due to their distinct advantages: non-invasive, avoidance of first-pass effect, improved bioavailability and reduction of systemic side effects. However, only a few drugs have been successfully delivered into blood stream to reach therapeutic levels without causing notable skin irritation or damage. Transbuccal drug delivery systems are still at research stage. The major barriers to transdermal and transbuccal drug delivery are stratum corneum of skin and epithelium of buccal tissue. The objective of this work was to overcome these barriers to significantly enhance transdermal and transbuccal delivery of hydrophilic drugs without causing major damage to skin and buccal tissue. In this work, iontophoresis, chemical
    [Show full text]
  • Public Assessment Report Scientific Discussion Alprostadil Recordati 2
    C B G M E B Public Assessment Report Scientific discussion Alprostadil Recordati 2 mg/g and 3 mg/g, cream (Alprostadil) NL/H/3303/001-002/DC Date: 21 December 2017 This module reflects the scientific discussion for the approval of Alprostadil Recordati 2 mg/g and 3 mg/g, cream. The procedure was finalised on 6 August 2015. For information on changes after this date please refer to the ‘steps taken after finalisation’ at the end of this PAR. C B G E B M List of abbreviations AE Adverse Event ANCOVA Analysis of Covariance ASMF Active Substance Master File AUC Area Under the Curve CEP Certificate of Suitability to the monographs of the European Pharmacopoeia CHMP Committee for Medicinal Products for Human Use CMD(h) Coordination group for Mutual recognition and Decentralised procedure for human medicinal products CMS Concerned Member State DDAIP Dodecyl-2-N,N-dimethylaminopropionate ED Erectile Dysfunction EDMF European Drug Master File EDQM European Directorate for the Quality of Medicines EEA European Economic Area EF Erectile Function ERA Environmental Risk Assessment EU European Union FDA Food and Drug Administration GCP Good Clinical Practice GLP Good Laboratory Practice HCl Hydrochloride ICH International Conference of Harmonisation IIEF International Index of Erectile Function IRB Institutional Review Board LADA Lauric Acid Diethanolamine LOGkow Logarithm of octanol/water partition coefficient LOQ Limit of Quantification LS Least Square MCID Minimal Clinically Important Difference MEB Medicines Evaluation Board in the Netherlands MAH Marketing Authorisation Holder PECsurfacewater Predicted Environmental Concentration in surface water Ph.Eur. European Pharmacopoeia PL Package Leaflet PSMF Pharmacovigilance System Master File PSUR Periodic Safety Update Report RH Relative Humidity RMP Risk Management Plan SAE Serious Adverse Event SD Standard Deviation SEP Sexual Encounter Profile SmPC Summary of Product Characteristics TSE Transmissible Spongiform Encephalopathy UK United Kingdom US United States 2/20 C B G E B M I.
    [Show full text]
  • Insights on Antifungal Drug - Miconazole Nitrate
    Human Journals Review Article July 2020 Vol.:18, Issue:4 © All rights are reserved by ABHIRAMI VENKATACHALAM et al. Insights on Antifungal Drug - Miconazole Nitrate Keywords: miconazole; systematic review; antifungal agents, dermatophytoses ABSTRACT ABHIRAMI VENKATACHALAM*, HARINI Miconazole nitrate, a synthetic derivative of imidazole, is an CHOWDARY VADLAMUDI antifungal agent used in the local treatment of vaginal, nail and 1*Acharya & BM Reddy College of Pharmacy, skin infections due to dermatophytes. Miconazole has been Soldevanahalli, Bengaluru – 560107. India. equally effective in both Candida and dermatophyte skin infections. However, it has been used effectively in chronic skin Submission: 26 June 2020 infections that have not satisfactorily reacted to other agents. It Accepted: 02 July 2020 is promising to have initial oral and intravenous miconazole Published: 30 July 2020 therapy in systemic candidiasis. Miconazole preparations are well tolerated and accepted. A greater understanding of the chemistry and specific mechanism of miconazole is critical to improve strategies and to develop better therapeutics. The purpose of this review is to enlighten the chemistry, pharmacology and the various methods used to enhance the www.ijppr.humanjournals.com solubility of miconazole. This review also includes the physicochemical properties, a brief about pharmacokinetic profile, disadvantages, drug interaction, uses and administration of miconazole nitrate. An assortment of methods has been developed in recent years that can improve its bioavailability. This article significantly reviews the latest published literature on diverse techniques for enhancing the bioavailability of miconazole. www.ijppr.humanjournals.com INTRODUCTION Miconazole is a synthetic antifungal imidazole that has been used effectively and safely in the treatment of superficial fungal infections for almost 40 years1.
    [Show full text]
  • View Annual Report
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to Commission file number 0-22245 APRICUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 87-0449967 (State or Other Jurisdiction of Incorporation or (I.R.S. Employer Organization) Identification No.) 6330 Nancy Ridge Drive, Suite 103, San Diego, CA 92121 (Address of Principal Executive Offices) (Zip Code) (858) 222-8041 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Exchange on Which Registered Common Stock, par value $.001 The NASDAQ Capital Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Coated Titanium Dioxide to Reduce Whitening Effect on Skin
    (19) TZZ ___T (11) EP 2 921 157 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.09.2015 Bulletin 2015/39 A61K 8/26 (2006.01) A61K 8/29 (2006.01) A61K 8/37 (2006.01) A61Q 17/04 (2006.01) (2006.01) (2006.01) (21) Application number: 14160519.6 A61K 8/02 C09C 1/36 (22) Date of filing: 18.03.2014 (84) Designated Contracting States: • Peters, Simone AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 21244 Buchholz (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Issleib, Martina PL PT RO RS SE SI SK SM TR 22955 Hoisdorf (DE) Designated Extension States: • Claus, Jürgen BA ME 37639 Bevern (DE) (71) Applicant: Symrise AG (74) Representative: Fabry, Bernd 37603 Holzminden (DE) IP2 Patentanwalts GmbH Schlossstrasse 523 (72) Inventors: 41238 Mönchengladbach (DE) • Johncock, William 21465 Reinbek (DE) (54) Coated titanium dioxide to reduce whitening effect on skin (57) The present invention relates to coated titanium dioxide particles, wherein at least one coating layer comprises an ester made from a mixture of fatty alcohol and C6 to C12 aliphatic acids as coating material. EP 2 921 157 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 921 157 A1 Description FIELD OF INVENTION 5 [0001] The present invention belongs to the area of cosmetic and pharmaceutical preparations, especially dermato- logical preparations and refers to the protection of the human skin and human hair against the harmful effects of ultraviolet (UV) radiation. The cosmetic and pharmaceutical preparations of the invention comprise a specially coated titanium dioxide which reduces the residual whitening effect, in particular on skin after application and improves the skin feel of the finished formulation.
    [Show full text]
  • Australian Public Assessment Report for Alprostadil
    Australian Public Assessment Report for alprostadil Proprietary Product Name: Proshaeos Sponsor: Commercial Eyes Pty Ltd June 2016 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. • An AusPAR is a static document; it provides information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Unnatural Β-Amino Acid Derivatives As Potential Transdermal Drug Delivery Systems
    Unnatural β-amino acid derivatives as potential transdermal drug delivery systems Rui Filipe Jesus Pereira Mestrado em Química Departamento de Química e Bioquímica 2019/2020 Orientador Maria Luísa Cardoso do Vale, Professora Auxiliar, FCUP Coorientador Maria de La Salette Reis, Professora Catedrática, FFUP Todas as correções determinadas pelo júri, e só essas, foram efetuadas. O Presidente do Júri, Porto, ______/______/_________ FCUP III Unnatural β-amino acid derivatives as potential transdermal drug delivery systems Agradecimentos Tem sido um privilégio trabalhar neste último ano no laboratório 2.24. do DQB e ter a possibilidade de completar a minha tese de mestrado, apesar das adversidades que este ano trouxe a todos nós. Gostaria de agradecer a todas as pessoas que tornaram isto possível. Primeiro, gostaria de agradecer à minha orientadora Profª. Luísa do Vale, pela oportunidade de trabalhar num projeto inteiramente novo dentro do seu grupo de investigação, pela confiança, apoio e orientação ao longo do ano. Uma palavra de apreço e gratidão para a Dr. Cidália Pereira pois foi ela que propôs o projeto no grupo e ajudou-me nos meus primeiros passos no projeto. Sem ela não teria conseguido chegar onde cheguei. Agradeço também à Dr. Sandra Silva pelo apoio contínuo ao longo do ano, pela sua experiência e conhecimento que me ajudaram, especialmente no estudo das propriedades físico-químicas dos compostos. Agradeço ao Prof. Eduardo Marques por ter disponibilizado o seu laboratório para a realização desses mesmos estudos, e pela orientação e contribuição na análise dos resultados. Um especial agradecimento para a minha coorientadora Profª. Salette Reis (FFUP) e à Dr.
    [Show full text]